Current Opinion in Investigational Drugs

More documents

Recommendations

Info

Current Opinion in Investigational Drugs Vol 7 No 1 January 2006 Editor in Chief Michael Williams USA Co-Editors Stanley Crooke USA Annette Doherty UK William Hagmann USA John Kemp GERMANY Jacob J Plattner USA Patent Editor Hermann AM Mucke AUSTRIA Thomson Scientific Middlesex House 34-42 Cleveland Street London W1T 4JE UK Tel +44 (0)20 7070 6565 Fax +44 (0)20 7070 6570 Email: TS.Custserv.EMEA@thomson. com Managing Editor Barbara Chan Email: barbara.chan@thomson.com In-house Editors Tracey Collins (Anti-infectives, Endocrine and Metabolics, and Oncological) Email: tracey.collins@thomson.com Paula Finn (Anti-inflammatory, Cardiovascular and Renal, and Nervous System) Email: paula.finn@thomson.com Editorial Board Janet Allen (UK) Rafael Apitz-Castro (Venezuela) John F Barrett (USA) Maria Belvisi (UK) Frank Bennett (USA) Andreas Billich (Austria) Norbert Bischofberger (USA) Roy Black (USA) Mel Blumenthal (USA) Frank Cerasoli (USA) Bruce Chabner (USA) Daniel Chu (USA) Kelvin Cooper (USA) Joseph Coyle (USA) Neal Cutler (USA) Mohsen Daneshtalab (Canada) Erik De Clercq (Belgium) Chet De Groat (USA) Errol DeSouza (Germany) Andy Dray (Canada) Mariano Elices (USA) Jilly Evans (USA) Tony Evans (Australia) Giora Feuerstein (USA) Alan C Foster (USA) Win Gutteridge (Switzerland) Jean Marc Herbert (France) Taff Jones (Canada) Loran Killar (USA) Gavin Kilpatrick (UK) George Koob (USA) Daniel Lane (USA) Alan Lewis (USA) John McCall (USA) Rodger McMillan (UK) Heinz Moser (USA) Bo Öberg (Sweden) Jose Palacios (Spain) Alan Palmer (UK) Michael Parnham (Croatia) Herbert Pinedo (Netherlands) Yves Pommier (USA) John Reed (UK) Malcolm Richardson (Finland) Steve Rosenberg (USA) Alessandro Sette (USA) Jim Sikorski (USA) John Souness (USA) Paul Smith (New Zealand) Ken Tanaka (USA) Eugene Thorsett (USA) Section Editors January 2006/July 2006 Central and Peripheral Nervous System Mike Briley (France), Mike Crowell (USA), Robert Davis (USA), Steve England (UK), Peter Goadsby (UK), Clifford Woolf (USA), Mike Wyllie (UK), Stevin Zorn (USA) February 2006/August 2006 Anti-infectives Robin Cooper (USA), Simon Croft (Switzerland), Christian Hubschwerlen (Switzerland), Jeffrey H Toney (USA), Alan Johnson (UK), Barney Koszalka (USA), Nicholas Meanwell (USA), Rino Rappuoli (Italy), John Rex (UK), David A Stevens (USA) March 2006/September 2006 Cardiovascular and Renal Frank Barone (USA), Tom Colatsky (USA), De-Zai Dai (China), Delvin Knight (USA), Brian Krause (USA), Keith E Suckling (UK), J Ruth Wu-Wong (USA) April 2006/October 2006 Endocrine and Metabolics Bruno Allolio (Germany), Franklyn Bolander (USA), Joy Hinson (UK), Nigel Levens (France), Terry Opgenorth (USA) May 2006/November 2006 Anti-inflammatory, Immunologicals and Biologicals Cynthia Darlington (New Zealand), Francis Dumont (USA), David Howat (France), Cees Korstanje (Netherlands), Tony Manning (USA), Randall Morris (USA), Neville Punchard (UK) June 2006/December 2006 Oncological Suresh Ambudkar (USA), Andrew Dorr (USA), David Gewirtz (USA), Michael Lotze (USA), Alain Rolland (USA), Edward Sausville (USA), Ian Stratford (UK), Mario Sznol (USA), Paul Workman (UK)
Current Opinion in Investigational Drugs Current Opinion in Investigational Drugs ISSN 1472-4472 is published monthly by: Thomson Scientific Middlesex House 34-42 Cleveland Street London W1T 4JE UK Tel: +44(0)20 7070 6565 Fax: +44(0)20 7070 6570 Email: TS.Custserv.EMEA@thomson.com Editorial Director Bernadette Swords Managing Editor (Journal) Barbara Chan Managing Editor (Evaluations) Sue Gotham In-house Editors (Journal) Tracey Collins, Paula Finn In-house Editors (Evaluations) Peter Aylett, Ruth Osiname, Tom Phillips Assistant Editors Timur Mehmet, Amanda Prince, Peter Stanislas Production Editor Debbie Wallbank Cover design © 2006 Andrew SR Featherstone - Research Graphix Copyright © 2005 The Thomson Corporation No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any electronic or other form without prior permission of the copyright owner. Article reprints are available through Thomson Scientific’s reprint service. For information contact: TS.Custserv.EMEA@thomson.com Advertising information Advertising is accepted in Current Opinion in Investigational Drugs. For further information on this and other products produced by Thomson Scientific, contact: Ken Forrest, Thomson Scientific, Holbrook House, 14 Great Queen Street, London, WC2B 5DF, UK Ken.Forrest@thomson.com, +44 (0)20 7424 2168 or visit our website at www.thomsoncurrentdrugs.com While every effort is made by the publisher and editorial board to see that no inaccurate or misleading data, opinion or statement appear in this journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers, the editorial board and section editors and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Current Opinion in Investigational Drugs is indexed by Index Medicus, MEDLINE, EMBASE/Excerpta Medica, Chemical Abstracts and Derwent Drug File. Printed in the UK Subscription information Annual subscription (twelve issues) Subscription rates include airspeed delivery North America Japan Rest of World Corporate $ 3641 ¥ 496,780 £ 2297 Additional copy $ 1849 ¥ 248,390 £ 1146 Academic rate $ 1849 ¥ 248,390 £ 1146 Orders All orders (except for Japan) should be placed with Thomson Scientific Customer Support and Order Processing Department 1st Floor, Holbrook House 14 Great Queen Street London WC2B 5DF UK Tel +44 (0) 20 7344 2800 Fax +44 (0)20 7344 2972 Orders for Japan Technomics Inc Nihonbashi TM Bldg 1-8-11 Nihonbashi Horidome-cho Chuo-ku Tokyo 103 Japan Tel +81 3 3666 2952 Fax +81 3 3666 2730 Subscription queries All enquiries should be addressed to Thomson Scientific Customer Support and Order Processing Department 1st Floor, Holbrook House 14 Great Queen Street London WC2B 5DF UK Tel +44 (0)20 7344 2800 Fax +44 (0)20 7344 2972 In case of particular difficulty please contact TS.Custserv.EMEA@thomson.com
Page 1: Current Opinion in Investigational
Page 5 and 6: Current Opinion in Investigational
Page 7 and 8: Paper alert A selection of interest
Page 9 and 10: Findings In vitro studies with poor
Page 11 and 12: Anti-infectives JANSSEN PHARMACEUTI
Page 13 and 14: Patent alert Patent alert provides
Page 15 and 16: OH O O WO-2005100336 (Aryx) C H 3 C
Page 17 and 18: educed serum NEFA and liver triglyc
Page 19 and 20: disease, hematological disease, hep
Page 21 and 22: Figure 1. The hype cycle. Visibilit
Page 23 and 24: 35. Huber LA: Is proteomics heading
Page 25 and 26: cases of pseudo-endophthalmitis [21
Page 27 and 28: Figure 1. The structures of selecte
Page 29 and 30: 4.8 mm 2 in vehicle-treated rats, w
Page 31 and 32: Drugs in development for Parkinson'
Page 33 and 34: Table 1. Examples of antiparkinsoni
Page 35 and 36: Table 3. Examples of neuroprotectiv
Page 37 and 38: 33. Novartis AG: Novartis shows dyn
Page 39 and 40: The mechanism of action of gabapent
Page 41 and 42: A specific binding site on voltage-
Page 43 and 44: prevent the release of excitatory n
Page 45 and 46: 68. Bertrand S, Nouel D, Morin F, N
Page 47 and 48: antagonized by the selective 5-HT1A
Page 49 and 50: 5-HT1A receptor activation Colpaert
Page 51 and 52: compromising the tolerability of op
Page 53 and 54:
50. Tricklebank MD: The behavioural
Page 55 and 56:
Figure 1. Important components of t
Page 57 and 58:
educe the inhibitory drive onto noc
Page 59 and 60:
58. Simon J, Wakimoto H, Fujita N,
Page 61 and 62:
against oxidative stress injury. VE
Page 63 and 64:
neurotrophic factor release, includ
Page 65 and 66:
50. Oosthuyse B, Moons L, Storkebau
Page 67 and 68:
pyridine were coupled via a palladi
Page 69 and 70:
In a study conducted in rats traine
Page 71 and 72:
glutamatergic and inhibitory GABA m
Page 73 and 74:
Metabolism (continued) Ispronicline
Page 75 and 76:
638398 The nicotinic acetylcholine
Page 77 and 78:
prolongation of survival of approxi
Page 79 and 80:
side effects were observed. The max
Page 81 and 82:
(n = 3 or 4 per cohort) has been co
Page 83 and 84:
Although subcutaneous administratio
Page 85 and 86:
583926 Aeolus Pharmaceuticals annou
Page 87 and 88:
Vivitrex Alkermes/Cephalon Christin
Page 89 and 90:
dorsal raphe nucleus. Immunohistoch
Page 91 and 92:
have been related to Vivitrex. Mean
Page 93 and 94:
Metabolism (continued) Vivitrex Hea
Page 95:
Erratum Current Opinion in Investig
show all

Current Opinion in Investigational Drugs

Create successful ePaper yourself

Delete template?

Save as template?